{"document_type": "article", "byline": {"contributor": "", "person": [{"role": "reported", "firstname": "Matt", "organization": "", "rank": 1, "lastname": "RICHTEL"}, {"role": "reported", "firstname": "Andrew", "organization": "", "rank": 2, "lastname": "POLLACK"}], "original": "By MATT RICHTEL and ANDREW POLLACK"}, "news_desk": "National", "slideshow_credits": null, "abstract": "Partnership between federal government and drug company Kite Pharma to develop cancer immunotherapy treatment raises concerns that taxpayers are getting raw deal; critics charge that taxpayers will end up paying twice for same drug--once to support its development and second time to purchase it--while company reaps financial benefit, whereas proponents say such partnerships are best way to deliver life-saving drugs to public (Series: Cell Wars).", "multimedia": [{"type": "image", "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbWide.jpg", "legacy": {"wide": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-articleLarge.jpg", "legacy": {"xlarge": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "Public Labs, Corporate Gains", "content_kicker": "Public Labs, Corporate Gains", "print_headline": "Taxpayers Finance Cancer Drug, but the Profits Will Be Private", "main": "Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits"}, "print_page": "1", "keywords": [{"value": "Cancer", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Immune System", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Kite Pharma Inc.", "is_major": "Y", "rank": "4", "name": "organizations"}, {"value": "National Cancer Institute", "is_major": "N", "rank": "5", "name": "organizations"}, {"value": "Belldegrun, Arie S", "is_major": "N", "rank": "6", "name": "persons"}, {"value": "Inventions and Patents", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Rosenberg, Steven A", "is_major": "N", "rank": "8", "name": "persons"}, {"value": "Series", "is_major": "Y", "rank": "9", "name": "subject"}], "snippet": "Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?...", "source": "The New York Times", "lead_paragraph": "Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?", "word_count": "3187", "pub_date": "2016-12-19T20:08:58+0000", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Health", "web_url": "http://www.nytimes.com/2016/12/19/health/harnessing-the-us-taxpayer-to-fight-cancer-and-make-profits.html", "_id": "58583e6395d0e03926076d65"}